qtrly revenue $473 million versus refinitiv ibes estimate of $473.4 million.
qtrly same-store sales increased 1.3%.
sees q3 pediatric cardiology volume down slightly by 2%.
qtrly pediatric hospitalist volumes increased 11.5% compared to q2 of 2019.
qtrly net sales of $25 million included $7 million gain on sale.
qtrly total g&a increased $3 million to $4 million.
sees fy adjusted ebitda above $270 million.
expects to end 2021 with adjusted ebitda to be below 2.5 times higher than prior year.
qtrly pediatric surgery volumes increased 8%.
qtrly net debt of $662 million versus $1,038 million at december 31, 2020.
compname reports third quarter 2021 results, announces $2 million to $3 million in annual g&a savings from building sale.
compname reports fourth quarter 2021 results and announces $29 million share repurchase program.
expect our dollar g&a spend for the second half of this year to be below $137 million, compared to $140 million during the first half of fiscal 2021.
compname reports fourth quarter and full year 2021 results; increases full-year 2021 guidance.
compname reports q4 adjusted ebitda of $270 million, up 27% from prior year.
qtrly operating cash flow of $70 million, up 70% from prior year.
